lol Truth hurts, nothing new under the sun about that. What, you think there's some time limit on holding a particular piece of idiocy up to your face? The only dckhed in the conversation is YOU, dckhed, and you're decidedly not worth my time, but I will deign to add in closing that I don't think I have to tell you exactly what you can do with yourself if you had even the least problem with my observation. See ya!
see the frustration , news out today CASC and LOXO presentation both ARRY's in which are partnered with ARRY , not a word mentioned by ARRY IR
cancerspeculator let me add a little more meat to your potatoes .....LOXO Briefing Document for the 29 June 2016 Oncologic Drugs Advisory Committee Pediatric Subcommittee on the FDA website, go to FDA "drugs" type in LOXO-101 in the search bar, a 49 page document on LOXO-101 should be your 1st hit.
During the afternoon session, information will be presented on the current unmet clinical need in the nearly uniformly fatal brain tumor, diffuse intrinsic pontine glioma (DIPG) which occurs predominantly in the pediatric age group. The diagnosis of DIPG is typically based on characteristic radiographic and clinical features in lieu of brain biopsy, and histological confirmation. Recent data has demonstrated that the biology and pathophysiology of these tumors differ. There are no approved drugs for this disease. Clinical investigators seek to exploit precision medicine approaches to DIPG and use potentially predictive information from the genomic signature of tumors at either diagnosis or relapse. This information can be used to select specific molecularly targeted drugs based on the genetic aberrations of an individual patient’s tumor. The Agency will seek the input of the subcommittee, including an assessment of benefit/risk given the potential for an adverse event associated with a surgical intervention in the brainstem.
On June 29, 2016, during the morning session, information will be presented for expert assessments related to exploring potential pediatric development plans for two products in various stages of development for adult cancer indications. The subcommittee will consider and discuss issues concerning diseases to be studied, patient populations to be included, and possible study designs in the development of these products for pediatric use. The discussion will also provide information to the Agency pertinent to the formulation of written requests for pediatric studies, if appropriate. The products under consideration are: (1) LOXO-101, presentation by Loxo Oncology, Inc., and (2) entrectinib, presentation by Ignyta, Inc
The eagle has landed in my trading account! Thanks to the selection I got from UltimateStockAlerts so make sure you look em up in google
Not able to get a hold of IR, over on stock twits somebody posted positive info on ONTY now CASC ONT-380
No ARRY PR its another secret, cant get hold of IR email or phone, one of the biggest event of the year PROMISED 2 NDA FILING FIRST HALF OF THE YEAR !!!!!!!!!! HOPE THEY PREWROTE THE PR FROM THE CARIBBEAN ISLANDS OR WILL THERE BE A DELAY ............................?
HARD TO STAY POSITIVE WITH THIS CURRENT LEADERSHIP
Did you see TSRO ? Shorts got squeezed when that drug for Ovarian cancer seems to have been successful.
How come ARRY does not do that type of thing ? Wasn't the latest data successful ? 100% move upward would put this stock at about $6.80 a share ? No ?
55K at about 1:23pm and another 51k at 1:24pm Someone just sold quite a bit. Put the stock into the red for the day. Not a good sign.
I thought they were going to file for the NDA ? Something tells me that is looking less likely
Leadership AMUK ACheerleader is different than a three pice big mouth that has a constant track record of failure Stay positive in light of having a Zero faults r CEO
Greed might save stockholders otherwise Ronny will destroy our chances
If partnerships dry up the company is finished Ronny has not a clue as to how to run a company
You bring up the point that suggests so much angst on this board: ARRY DOES have a rich pipeline, but their partners are doing all of the heavy lifting and CEO Squarer just seems to cheerlead from the sidelines. He's responsible in getting these drugs approved. He continually misses deadlines and hence a stock price mired in the low $3s. l'll try to be positive, but company leadership makes it hard.